Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
boston blog main
boston top stories
life sciences
5
×
national blog main
5
×
alnylam pharmaceuticals
drugs
clinical trials
fda
national top stories
patisiran
rna interference
akcea therapeutics
aminolevulinic acid
biotech
givosiran
hereditary transthyretin amyloidosis
inotersen
new york blog main
new york top stories
onpattro
san diego blog main
san diego top stories
tafamidis
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
barry greene
biopharma
boston university
dan ollendorf
deals
duchenne
europe blog main
europe top stories
european medicines agency
harvard pilgrim health care
institute for clinical and economic review
john berk
What
medicine
5
×
rna
5
×
alnylam
fda
drug
interference
rnai
second
ago
approval
gene
historic
pharmaceuticals
seek
speedy
uses
approve
approves
awaits
betting
billion
biological
biopharma
cells
cleared
crossed
data
deal
decades
decision
discovered
duchenne
ema
employ
europe
far
fingers
follows
friday
harmful
Language
unset
Current search:
rna
×
medicine
×
" life sciences "
×
" national blog main "
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision